HER-2/neu Peptide Breast Cancer Vaccines: Current Status and Future Directions

Breast Diseases

Volumn 17, Issue 4, 2007, Pages 318-320

  Mittendorf, Elizabeth A ^a   Peoples, George E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248999139     PISSN: 1043321X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-321X(07)80101-9     Document Type: Article

References (10)

1. Slamon D., Godolphin W., Jones L., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
2. Knutson K., Schiffman K., Cheever M., et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8 (2002) 1014-1018
3. Murray J., Gillogly M., Przepiorka D., et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8 (2002) 3407-3418
4. Zaks T., and Rosenberg S. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58 (1998) 4902-4908
5. Peoples G., Gurney J., Hueman M., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23 (2005) 7536-7545
6. Disis M., Grabstein K., Sleath P., et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5 (1999) 1289-1297
7. Mittendorf E., Storrer C., Foley R., et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106 (2006) 2309-2317
8. Slingluff Jr. C., Petroni G., Yamshchikov G., et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22 (2004) 4474-4485
9. Kallinteris N., Powell D., Blackwell C., et al. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front Biosci 11 (2006) 46-58
10. Mittendorf E., Storrer C., Shriver C., et al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13 (2006) 1085-1098